Optimizing Frontline Treatment Approaches in EGFRm Metastatic NSCLC - Episode 11
Evaluating Pemetrexed Exposure in FLAURA2: Key Findings and Treatment Implications
Panelists discuss how the FLAURA2 pemetrexed exposure subanalysis showed that patients could benefit from the regimen even if they didn't complete the full maintenance period as prescribed in the trial.
FLORA-2 Outcomes Based on Pemetrexed Exposure
Main Discussion Topics:
- Analysis of FLAURA2 outcomes based on duration of pemetrexed exposure
- Implications for real-world implementation of the regimen
- Factors influencing decisions about continuing vs discontinuing pemetrexed
Key Points for Physicians:
- Median exposure to platinum-based chemotherapy was 3 months; pemetrexed was 8.3 months; osimertinib was 22 months
- Similar progression-free survival was observed between patients receiving 3 to 9 months and 9 to 18 months of pemetrexed
- Decisions to discontinue pemetrexed are typically driven by toxicity or patient preference rather than efficacy concerns
Notable Insights:
Patients who received at least some pemetrexed maintenance beyond the initial combination phase appeared to derive the benefit of the regimen, suggesting flexibility in maintenance duration.
Clinical Significance:
Real-world implementation of FLAURA2 can incorporate individualized approaches to maintenance therapy duration while preserving efficacy benefits.
Related Content:
